European Pharmaceutical Pricing and Reimbursement Conference 2011

2011 has brought with it huge changes to the health care landscape - the global economic crisis and rising healthcare costs have caused governments to take cautious approaches towards pricing and reimbursement (P&R) for pharmaceuticals.

With aging and expanding populations, improving standards of living has meant there has been a significant burden on the healthcare systems. Emerging markets are also finding it challenging to meet the increasing expectations for healthcare, despite rapid economic growth. This event will therefore review the key challenges and developments in the emerging markets, established markets and the US with their impact on international healthcare.

The agenda for this event is currently being finalised. Among other subjects, the conference shall be focusing on the following areas:

-Emerging Markets
-Established Markets
-Obama Impact on the International Healthcare
-Value Based Pricing
-AMNOG
-Market Access
-Medical Devices
-Orphan Drugs
-Impact of NICE